Abstract
Heart failure with reduced ejection fraction is a syndrome consisting of symptoms (dyspnoea, fatigue, swelling) and/or signs of congestion (pulmonary crackles, oedema). It is caused by structural and/or functional pathologies, most commonly ischaemic heart disease, entailing elevated cardiac filling pressures and can result in low cardiac output. Medical treatment has evolved during the recent decades as outlined in this review, and a 4-pillar treatment strategy is recommended including a renin-angiotensin-aldosterone system blocker or sacubitril/valsartan, a betablocker, a mineralocorticoid antagonist, and an SGLT2 inhibitor.
Bidragets oversatte titel | Not Available |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 186 |
Udgave nummer | 42 |
ISSN | 0041-5782 |
DOI | |
Status | Udgivet - 14 okt. 2024 |
Emneord
- Humans
- Heart Failure/drug therapy
- Mineralocorticoid Receptor Antagonists/therapeutic use
- Adrenergic beta-Antagonists/therapeutic use
- Chronic Disease
- Ventricular Dysfunction, Left/drug therapy
- Angiotensin Receptor Antagonists/therapeutic use
- Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
- Stroke Volume
- Angiotensin-Converting Enzyme Inhibitors/therapeutic use